Radiotherapy Clinical Trial
Official title:
Efficacy and Safety of Concurrent Sintilimab and Radiotherapy With Immunonutrition Support in Esophageal Cancer: A Phase II Multicenter Clinical Trial
At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status. However, cCRT has substantial toxic effects, and a large number of patients with older age, malnutrition and other morbidities, cannot tolerate cCRT. Several phase II trials showed combining PD-1 inhibitor with definitive cCRT provided encouraging activity and acceptable toxicity in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). Therefore, this single-arm, multicenter, phase II trial aims to assess the efficacy and safety of immunotherapy plus radiotherapy with immunonutrition support in patients with LA-ESCC and positive PD-L1 expression who are intolerant to cCRT.
This single-arm trial is designed to evaluate the efficacy and safety of concurrent immunotherapy (sintilimab) plus radiotherapy with immunonutrition support (enteral nutritional emulsion (TPF-T) followed by consolidation immunotherapy in inoperable patients with locally advanced or early stage esophageal squamous cell carcinoma , who are PD-L1 positive expression and intolerant to cCRT. The eligible patients will receive concurrent treatment consisting of total dose of 50-60 Gy in 25-30 fractions and 200 mg of sintilimab administered every three weeks, along with enteral nutritional emulsion (TPF-T) support (600-1600 ml per day according to the nutrition status evaluation). The primary outcome is 1-year progression-free survival (PFS) rate. The investigators hypothesized PD-L1 inhibitor plus radiotherapy will improve the 1-year PFS from 40% to 60%. Then, 58 patients will be needed in total. The secondary outcomes will include objective response rate (ORR), overall survival (OS), progression-free and overall survival, and incidence of adverse events. This study is approval by the National GCP Center for Anticancer Drugs, Independent Ethics Committee, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College (Study ID: 24/074-4354). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03212742 -
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
| Recruiting |
NCT06120127 -
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
|
Phase 2 | |
| Recruiting |
NCT05176002 -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT02661152 -
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
|
Phase 3 | |
| Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
| Completed |
NCT01168479 -
FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT03658343 -
T2* MRI Analysis for Sarcoma
|
N/A | |
| Completed |
NCT03280719 -
Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions
|
N/A | |
| Recruiting |
NCT05514327 -
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
|
N/A | |
| Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
| Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Recruiting |
NCT03370926 -
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
|
N/A | |
| Active, not recruiting |
NCT03870919 -
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT02428049 -
Radiation Pneumonitis After SBRT for NSCLC
|
||
| Recruiting |
NCT04923620 -
Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
|
||
| Active, not recruiting |
NCT05371795 -
Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device
|
N/A | |
| Recruiting |
NCT03210428 -
Quantitative MR Imaging in Locally Advanced Cervical Cancer
|